Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.46 |
| ▸ | SRPK1 | Q96SB4 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MYC | P01106 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | LDHA | P00338 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30501712 | 1.00 | KDM4E (0.54) | KDM4ECYP1A2CYP2C19PTGS2TAS1R3 | |
| SCHEMBL7126700 | 0.79 | KDM4E (0.51) | KDM4EPTGS2SRPK1ENPP2HDAC2 | |
| SCHEMBL23091182 | 0.78 | ERN1 (0.55) | KDM4ECYP1A2CYP2C19PTGS2SMN1; SMN2 | |
| SCHEMBL13088447 | 0.76 | NFATC1 (0.48) | KDM4ECYP1A2CYP2C19SRPK1SMN1; SMN2 | |
| SCHEMBL23091223 | 0.76 | PDE4A (0.59) | KDM4ECYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL23091158 | 0.76 | KDM4E (0.62) | KDM4ECYP1A2CYP2C19SMN1; SMN2MMP13 | |
| SCHEMBL18551808 | 0.74 | NPC1 (0.47) | PTGS2 | |
| SCHEMBL23091202 | 0.74 | MMP13 (0.60) | KDM4ECYP1A2CYP2C19SMN1; SMN2MMP13 | |
| SCHEMBL23091209 | 0.74 | KDM4E (0.57) | KDM4ECYP1A2CYP2C19PTGS2SMN1; SMN2 | |
| SCHEMBL8514379 | 0.74 | TAS1R3 (0.68) | CYP1A2CYP2C19TAS1R3TAS1R1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3805210-B1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | AUTOPHAGYSCIENCES INC (KR) | 2023-11-29 | — | — | EP | claimed |
| CN-112004807-B | Compounds and pharmaceutical compositions comprising the same | 自体吞噬科学有限公司 | 2023-07-18 | — | — | CN | claimed |
| US-11407744-B2 | Compound and pharmaceutical composition comprising same | Autophagysciences Inc. (KR) | 2022-08-09 | — | — | US | claimed |
| EP-3805210-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Autophagysciences, Inc (KR) | 2021-04-14 | — | — | EP | claimed |
| US-20210078987-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Autophagysciences Inc. (KR) | 2021-03-18 | — | — | US | claimed |
| EP-3805210-B1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | AUTOPHAGYSCIENCES INC (KR) | 2023-11-29 | — | — | EP | disclosed |
| CN-112004807-B | Compounds and pharmaceutical compositions comprising the same | 自体吞噬科学有限公司 | 2023-07-18 | — | — | CN | disclosed |
| US-11407744-B2 | Compound and pharmaceutical composition comprising same | Autophagysciences Inc. (KR) | 2022-08-09 | — | — | US | disclosed |
| EP-3805210-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Autophagysciences, Inc (KR) | 2021-04-14 | — | — | EP | disclosed |
| US-20210078987-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Autophagysciences Inc. (KR) | 2021-03-18 | — | — | US | disclosed |
| US-20210078987-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Autophagysciences Inc. (KR) | 2021-03-18 | — | — | US | disclosed |
| CN-112004807-A | Novel compounds and pharmaceutical compositions comprising said compounds | 自体吞噬科学有限公司 | 2020-11-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11407744-B2 | Compound and pharmaceutical composition comprising same | TFEB, ATG7, BECN1 | KDM4E 3653/4885CYP1A2 4347/4885CYP2C19 4643/4885 |
| US-20210078987-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | TFEB, ATG7, BECN1 | KDM4E 3445/4885CYP1A2 4544/4885CYP2C19 4772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.